跳到主要內容

Mathew Aby J. 的 Form 4 申報

Biolife Solutions Inc(BLFS),2024/3/12 申報

申報編號
0001628280-24-010747
申報時間
2024/3/12
交易日
2024/3/8-3/12
申報延遲
4 天
10b5-1 計畫
有勾選

這份申報列了 4 筆非衍生性交易。公開市場賣出合計 $11.4 萬。交易後 4 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Mathew Aby J.CIK 0001556355高階主管(執行副總裁、科學長)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2024/3/8Common StockA公司授予取得+25,470–F1–300,684直接
2024/3/8Common StockA公司授予取得+26,286–F2–326,970直接
2024/3/11Common StockS賣出處分−313$17.42−$5,452.46326,657直接
2024/3/12Common StockS賣出處分−6,521$16.60−$108,248.6320,136直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation.

表 I 有 1 筆交易的價格引用這則附註。

F2

The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)